Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00508651 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age
A Phase 1 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00508651 is a Phase 1 study that was terminated before completion, run by MedImmune. The registered enrollment target is 30 participants.
The verdict
NCT00508651, a Phase 1 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective of this study is to describe the safety and tolerability of 3 doses of MEDI-560 at 10\^5 TCID50 when administered to children 6 to \< 12 months of age who are HPIV3 (human parainfluenza virus type 3) seronegative at baseline and to infants 1 to \< 3 months of age regardless of baseline serostatus.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MEDI-560
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00508651
The ClinicalTrials.gov registry entry for NCT00508651 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00508651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00508651 about?
NCT00508651 is a clinical study titled "A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age". The primary objective of this study is to describe the safety and tolerability of 3 doses of MEDI-560 at 10\^5 TCID50 when administered to children 6 to \< 12 months of age who are HPIV3 (human parainfluenza virus type 3) seronegative at baseline and to infants 1 to \< 3 months of age regardless of ...
What is the current status of trial NCT00508651?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2007-10. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00508651?
The interventions under investigation include: Placebo (BIOLOGICAL), MEDI-560 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00508651?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.